The MD Anderson Symptom Inventory-Heart Failure (MDASI-HF): Instrument Development and Psychometric Testing

2.50
Hdl Handle:
http://hdl.handle.net/10755/154533
Type:
Presentation
Title:
The MD Anderson Symptom Inventory-Heart Failure (MDASI-HF): Instrument Development and Psychometric Testing
Abstract:
The MD Anderson Symptom Inventory-Heart Failure (MDASI-HF): Instrument Development and Psychometric Testing
Conference Sponsor:Sigma Theta Tau International
Conference Year:2006
Author:Fadol, Anecita P., RN, MSN, FNP
P.I. Institution Name:University of Texas MD Anderson Cancer Center
Title:Nurse Practitioner
Patients with cancer and heart failure experience an unacceptable level of symptoms as the disease progresses.  Inadequate management of these symptoms results in frequent unnecessary hospitalization and poor quality of life. However, a validated instrument for assessment of symptoms in this patient population is lacking. This pilot study is an initial evaluation of the reliability and validity of an instrument for symptom assessment of cancer patients with heart failure entitled the MD Anderson Symptom Inventory-Heart Failure (MDASI-HF). Thirty two patients diagnosed with cancer and heart failure provided ratings on the 24 symptom severity questions and six interference items measuring symptom burden. Criterion validity showed moderate correlation scores of the MDASI-HF with the Eastern Cooperative Oncology Group (ECOG) performance status (r = .467 -.731; p = .000 - .042) and the New York Heart Association (NYHA) functional classification (r = .439 -.719; p =.000 - .042). Construct validity was determined using factor analysis, which yielded a six factor solution accounting for 80% of the cumulative variance.  Internal consistency reliability showed a Cronbach?s coefficient alpha of .936 for the severity items and .906 for the interference items.  Preliminary results suggest that the MDASI-HF appears to be valid tool in examining symptom prevalence and burden in cancer patients with heart failure.  Further study is needed to establish the reliability and validity of the instrument.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleThe MD Anderson Symptom Inventory-Heart Failure (MDASI-HF): Instrument Development and Psychometric Testingen_GB
dc.identifier.urihttp://hdl.handle.net/10755/154533-
dc.description.abstract<table><tr><td colspan="2" class="item-title">The MD Anderson Symptom Inventory-Heart Failure (MDASI-HF): Instrument Development and Psychometric Testing</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2006</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Fadol, Anecita P., RN, MSN, FNP</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">University of Texas MD Anderson Cancer Center</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Nurse Practitioner</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">afadol@mdanderson.org</td></tr><tr><td colspan="2" class="item-abstract">Patients with cancer and heart failure experience an unacceptable level of symptoms as the disease progresses. &nbsp;Inadequate management of these symptoms results in frequent unnecessary hospitalization and poor quality of life. However, a validated instrument for assessment of symptoms in this patient population is lacking. This pilot study is an initial evaluation of the reliability and validity of an instrument for symptom assessment of cancer patients with heart failure entitled the MD Anderson Symptom Inventory-Heart Failure (MDASI-HF). Thirty two patients diagnosed with cancer and heart failure provided ratings on the 24 symptom severity questions and six interference items measuring symptom burden. Criterion validity showed moderate correlation scores of the MDASI-HF with the Eastern Cooperative Oncology Group (ECOG) performance status (r = .467 -.731; p = .000 - .042) and the New York Heart Association (NYHA) functional classification (r = .439 -.719; p =.000 - .042). Construct validity was determined using factor analysis, which yielded a six factor solution accounting for 80% of the cumulative variance.&nbsp; Internal consistency reliability showed a Cronbach?s coefficient alpha of .936 for the severity items and .906 for the interference items.&nbsp; Preliminary results suggest that the MDASI-HF appears to be valid tool in examining symptom prevalence and burden in cancer patients with heart failure.&nbsp; Further study is needed to establish the reliability and validity of the instrument.</td></tr></table>en_GB
dc.date.available2011-10-26T13:04:28Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T13:04:28Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.